Cited 0 times in

Exploring Molecular Genetic Alterations and RAF Fusions in Melanoma: A Belvarafenib Expanded Access Program in Patients with RAS/RAF-Mutant Melanoma

DC Field Value Language
dc.contributor.author김창곤-
dc.contributor.author노미령-
dc.contributor.author류향주-
dc.contributor.author신상준-
dc.contributor.author오병호-
dc.contributor.author이청-
dc.contributor.author정기양-
dc.contributor.author정민규-
dc.contributor.author김규현-
dc.date.accessioned2024-06-14T03:11:06Z-
dc.date.available2024-06-14T03:11:06Z-
dc.date.issued2024-06-
dc.identifier.issn1083-7159-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/199800-
dc.description.abstractBackground: Melanoma incidence is on the rise in East Asia, yet studies of the molecular landscape are lacking in this population. We examined patients with melanoma who underwent next-generation sequencing (NGS) at a single tertiary center in South Korea, focusing on patients harboring NRAS or RAF alterations who received belvarafenib, a pan-RAF dimer inhibitor, through the Expanded Access Program (EAP). Patients and methods: Data were collected from 192 patients with melanoma who underwent NGS between November 2017 and May 2023. Variant call format data were obtained and annotated. Patients in the EAP received 450 mg twice daily doses of belvarafenib. Results: Alterations in the RAS/RTK pathway were the most prevalent, with BRAF and NRAS alteration rates of 22.4% and 17.7%, respectively. NGS enabled additional detection of fusion mutations, including 6 BRAF and 1 RAF1 fusion. Sixteen patients with NRAS or RAF alterations received belvarafenib through the EAP, and disease control was observed in 50%, with 2 patients demonstrating remarkable responses. Conclusions: Our study highlights the value of NGS in detecting BRAF, NRAS mutations and RAF fusions, expanding possibilities for targeted therapies in malignant melanoma. Belvarafenib showed clinical benefit in patients harboring these alterations. Ongoing trials will provide further insights into the safety and efficacy of belvarafenib.-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.languageEnglish-
dc.publisherAlphaMed Press-
dc.relation.isPartOfONCOLOGIST-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHFemale-
dc.subject.MESHGTP Phosphohydrolases / genetics-
dc.subject.MESHHigh-Throughput Nucleotide Sequencing / methods-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMelanoma* / drug therapy-
dc.subject.MESHMelanoma* / genetics-
dc.subject.MESHMelanoma* / pathology-
dc.subject.MESHMembrane Proteins / genetics-
dc.subject.MESHMiddle Aged-
dc.subject.MESHMutation*-
dc.subject.MESHProtein Kinase Inhibitors / therapeutic use-
dc.subject.MESHProto-Oncogene Proteins B-raf* / genetics-
dc.subject.MESHProto-Oncogene Proteins c-raf / genetics-
dc.titleExploring Molecular Genetic Alterations and RAF Fusions in Melanoma: A Belvarafenib Expanded Access Program in Patients with RAS/RAF-Mutant Melanoma-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorKyoo Hyun Kim-
dc.contributor.googleauthorSungmin Cho-
dc.contributor.googleauthorYeyeong Jeong-
dc.contributor.googleauthorEun Sil Baek-
dc.contributor.googleauthorChung Lee-
dc.contributor.googleauthorHyang-Joo Ryu-
dc.contributor.googleauthorYoung Su Noh-
dc.contributor.googleauthorYoon-Hee Hong-
dc.contributor.googleauthorKee Yang Chung-
dc.contributor.googleauthorMi Ryung Roh-
dc.contributor.googleauthorByung Ho Oh-
dc.contributor.googleauthorChang Gon Kim-
dc.contributor.googleauthorMinkyu Jung-
dc.contributor.googleauthorSang Joon Shin-
dc.identifier.doi10.1093/oncolo/oyae018-
dc.contributor.localIdA05991-
dc.contributor.localIdA01278-
dc.contributor.localIdA06168-
dc.contributor.localIdA02105-
dc.contributor.localIdA02367-
dc.contributor.localIdA06477-
dc.contributor.localIdA03582-
dc.contributor.localIdA03606-
dc.relation.journalcodeJ02415-
dc.identifier.eissn1549-490X-
dc.identifier.pmid38470950-
dc.subject.keywordRAF fusion-
dc.subject.keywordbelvarafenib-
dc.subject.keywordhigh-throughput nucleotide sequencing-
dc.subject.keywordmelanoma-
dc.contributor.alternativeNameKim, Chang Gon-
dc.contributor.affiliatedAuthor김창곤-
dc.contributor.affiliatedAuthor노미령-
dc.contributor.affiliatedAuthor류향주-
dc.contributor.affiliatedAuthor신상준-
dc.contributor.affiliatedAuthor오병호-
dc.contributor.affiliatedAuthor이청-
dc.contributor.affiliatedAuthor정기양-
dc.contributor.affiliatedAuthor정민규-
dc.citation.volume29-
dc.citation.number6-
dc.citation.startPagee811-
dc.citation.endPagee821-
dc.identifier.bibliographicCitationONCOLOGIST, Vol.29(6) : e811-e821, 2024-06-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Dermatology (피부과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.